Where does AnaCardio's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across AnaCardio's 1 recorded funding rounds.

Premier Alternatives

AnaCardio

Stockholm, Sweden · Founded 2017 · Privately Held (backing)

Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. AnaCardio is based in Stockholm, Sweden and was founded in 2017. It was valued at $293 million at its Series B in Sep 2026, the last priced event on record. It has raised $44.2 million across 1 recorded round; the latest was a Series B in Sep 2026.

PMV mark · valuation

$292.9M

Oct 2026

Priced at

its Series B

Sep 2026

Total raised

$44.2M

Last round

Series B

Sep 2026

Cap table — not yet on record

AnaCardio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of AnaCardio with a free account

·The post-money valuation on its round
·The complete investor list: 13 names
·Watch AnaCardio: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about AnaCardio

Where does AnaCardio's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across AnaCardio's 1 recorded funding rounds.